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Abstract
Background: Alzheimer’s disease is associated with amyloid-beta (Aβ)-induced microglia activation. This
pro-inflammatory response promotes neuronal damage, and therapies are sought to limit microglial activation.
Screening efforts to develop new pharmacological inhibitors require a robust in vitro cell system. Current models
lack significant responses to Aβ, and their use in examining age-related neurodegenerative diseases is questionable.
For example, the commonly used BV-2 microglial line was derived from embryonic mononuclear cells and its
activation by various stimuli is limited. To this end, we have established a new immortalized microglial (IMG) cell
line from adult murine brain. The objective of this study was to characterize Aβ-induced activation of IMG cells, and
here, we demonstrate the ability of cannabinoids to significantly reduce this inflammatory response.
Methods: Microglial cells derived from adult murine brain were immortalized via infection with the v-raf/v-myc
retrovirus under conditions that selectively promote microglia growth. The presence or absence of markers CD11b
and F4/80 (microglial), NeuN (neuronal), and GFAP (astrocytic) was assessed by immunofluorescence microscopy
and western blotting. Using IMG and BV-2 cells, levels of pro- and anti-inflammatory transcripts in response to
extracellular stimuli were determined by quantitative PCR (qPCR). Phagocytosis of fluorescent beads and fluorescein
isothiocyanate (FITC)-labeled Aβ oligomers was assessed using flow cytometry and fluorescence microscopy.
FITC-Aβ uptake was quantified using a fluorescence plate reader. The ability of cannabinoids to mitigate
Aβ-induced expression of inducible nitric oxide synthase (iNOS) was evaluated.
Results: IMG cells express the microglial markers CD11b and F4/80 but not NeuN or GFAP. Relative to BV-2 cells,
IMG cells increased iNOS (>200-fold) and Arg-1 (>100-fold) in response to pro- and anti-inflammatory stimuli. IMG
cells phagocytose foreign particles and Aβ oligomers, with the latter trafficked to phagolysosomes. Aβ-induced
activation of IMG cells was suppressed by delta-9-tetrahydrocannabinol and the CB2-selective agonist JWH-015
in a time- and concentration-dependent manner.
Conclusions: IMG cells recapitulate key features of microglial cell activation. As an example of their potential
pharmacological use, cannabinoids were shown to reduce activation of Aβ-induced iNOS gene expression. IMG
cells hold promising potential for drug screening, mechanistic studies, and functional investigations directed
towards understanding how Aβ interacts with microglia.
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Background
Microglial cells, often thought of as the resident macro-
phages of the central nervous system (CNS), act as the
immune cells of the brain and spinal cord. Microglia be-
come activated by disturbances in the homeostasis of
their local microenvironment. Activation of microglial
cells results in a cascade of phenotypic changes includ-
ing, but not limited to, morphology, transcription, and
cytokine production. While there are varying degrees of
microglia activation [1], two main polarized states are
established: a pro-inflammatory reactive state induced by
exposure to stimuli like lipopolysaccharide (LPS) and
interferon-γ (IFNγ) and an anti-inflammatory state to
promote repair and resolution of inflammation, which is
induced by factors such as interleukin-4 (IL-4) and
interleukin-13 (IL-13) [2, 3].
The ability to polarize between reactive and repair
states allows microglia to actively transition from an
immune-stimulating antimicrobial phenotype to one that
supports tissue repair and resolution of inflammation
[1]. Dysregulation of the activation state of microglial
cells can be detrimental to CNS health. Several neurode-
generative diseases including Alzheimer’s disease and
Parkinson’s disease have been attributed to chronically
activated pro-inflammatory microglial cells [4–10].
Chronic activation of microglial cells is thought to result
from multiple stimuli ranging from systemic infection,
misfolded proteins, or cellular debris within the CNS
[5]. In the case of the Alzheimer’s disease brain, micro-
glia are activated by amyloid-β (Aβ) peptides, which are
cleared from the interstitium by phagocytosis. As the
disease persists, microglia become chronically activated
by Aβ peptides and produce excessive amounts of pro-
inflammatory cytokines leading to autocrine reduction
of microglial Aβ receptors and ultimately decreased Aβ
clearance from the interstitium [11].
Regardless of the provoking stimuli, efforts to target
activated microglia for the treatment of certain neuro-
degenerative diseases include pharmacological re-
polarization to the more anti-inflammatory phenotype
[2, 12]; cannabinoids represent one class of pharmaco-
logical agents currently being examined. Unfortunately,
studies of microglial cell function are limited by low
yields of primary microglial cells (approx. 500,000 cells
per adult mouse brain) along with potential activation
during isolation. Several immortalized microglia cell
lines have been generated [13, 14] and provide experi-
mental advantages of a homogeneous population of cells
that can proliferate more rapidly. Most microglial cell
studies have relied on the murine BV-2 cell line which
was immortalized by infection of embryonic brain
mononuclear cells with a v-raf/v-myc oncogene-carrying
retrovirus [14, 15]. However, more recent evidence sug-
gests that microglial cells of the adult brain are derived
from myeloid progenitors [16]. Therefore, the embryonic
origin of BV-2 cells raises questions about their epigen-
etic state and whether they truly resemble resident
microglia in the adult brain.
Here, we report the generation and characterization of
a novel cell line using microglia purified from the adult
mouse brain. These cells were established using the Per-
coll gradient isolation followed by culture conditions
that selectively promote microglial cell growth [17, 18].
This study characterizes the properties of the immortal-
ized microglia (IMG cells), which express markers spe-
cific to primary adult microglial cells (CD11b and F4/
80). IMG cells respond to pro-inflammatory (LPS and
Aβ) or anti-inflammatory (IL-4) stimuli. The changes in-
duced by LPS, Aβ, and IL-4 are far greater than those in-
duced in BV-2 cells. IMG cells provide a model system
for drug candidate screening as evidenced by inhibition
of Aβ-induced M1 activation by the cannabinoids delta-
9-tetrahydrocannabinol (THC) and JWH-015. Lastly, we
demonstrate that IMG cells retain the ability to en-
gulf fluorescent beads and fluorescein isothiocyanate
(FITC)-labeled Aβ by phagocytosis, functions that are
important to explore experimentally to further our
understanding of complex Aβ-microglia interactions
in Alzheimer’s disease.
Methods
Cell culture and reagents
IMG, C6 glioma, and BV-2 cells were cultured in Dul-
becco’s modified Eagle medium (DMEM) with high glu-
cose (4.5 g/L), 10 % fetal bovine serum (FBS) and
penicillin/streptomycin (100 U/mL). SH-SY5Y cells were
maintained in DMEM/F12 (1:1 ratio) media with 10 %
FBS and penicillin/streptomycin (100 U/mL). IFNγ, IL-
1β, TNF-α, IL-4, IL-6, and IL-13 were purchased from
Peprotech (Rocky Hill, NJ). LPS, Ac-YVAD-CMK, delta-
9-tetrahydrocannabinol, and JWH-015 were purchased
from Sigma Aldrich. Adenosine triphosphate (ATP) was
purchased from Amersham Biosciences.
Primary microglia isolation and generation of IMG cell
line
Microglia were purified from adult brain using gradient
isolation methods [19]. Proliferation and retroviral infec-
tion was carried out in medium conditioned with growth
factors GM-CSF and M-CSF to selectively support
microglial growth. Briefly, 8-week-old C57BL/6J mice
were perfused with ice-cold phosphate-buffered saline
(PBS) through the left ventricle. After collagenase diges-
tion of brain slices, and debris removal, microglia were
isolated on Percoll gradients (30 %–37 %–70 %) and col-
lected at the 37–70 % interface. Microglial cells were
maintained in DMEM (5 mM glucose), 10 % FBS, and
1 % P/S using 30 % L929 cell-conditioned medium to
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induce proliferation of microglial cells. Cells proliferated
at days 5–10 after plating. To immortalize the cells, they
were re-plated and infected with v-raf/v-myc retrovirus
(J2-conditioned medium [20]), supplemented with 30 %
L929-conditioned media and 4 μg/mL polybrene. The
next day, the medium was replaced by DMEM (4.5 g/L
glucose), 10 % FBS, and 1 % P/S.
Flow cytometry
IMG cells were grown on a 10-cm tissue culture dish
until 80 % confluent. After addition of 5 mL fresh media,
cells were lifted off the dish using a cell scraper. IMG
cells were resuspended to 1 × 108 cells/mL and incu-
bated with fluorescently conjugated CD11b (Alexa 647
conjugate; Serotec), F4/80 (allophycocyanin (APC) con-
jugate; Caltag), or appropriate isotype control (BioLe-
gend) antibodies (1:10 dilution) in the dark for 15 min at
4 °C. Cells were then washed three times with 2 mL cell-
staining buffer (BioLegend). After washing, cells were re-
suspended in cell-staining buffer and were analyzed by
flow cytometry (FACSCalibur, BD Biosciences). Acquired
data were analyzed using FlowJo data analysis software
(FlowJo, LLC).
Fluorescence microscopy
IMG and SH-SY5Y cells grown on poly-D-lysine-coated
coverslips were fixed for 20 min with 4 % formaldehyde
at 4 °C in PBS containing 0.5 mM MgCl2 and 1 mM
CaCl2 (PBS
++). Cells were then permeabilized with 0.5 %
Triton-X100 in PBS++ for 5 min at room temperature.
After blocking with 1 % bovine serum albumin (BSA)
and 0.3 M glycine in PBS++ for 1 h at room temperature,
cells were incubated for 1 h at room temperature with
anti-NeuN (Millipore, MAB377) (1:100), anti-F4/80
(Caltag, MF48020) (1:100), or anti-CD11b (Serotec)
(1:100). Cells were then washed and incubated for 1 h at
room temperature with Alexa Fluor 568-conjugated
anti-rabbit or anti-mouse antibody (1:1000, Invitrogen)
in 1 % BSA in PBS++. Coverslips were mounted onto
glass slides using DakoCytomation fluorescent mounting
medium (Carpinteria, CA). Images were obtained using
a Zeiss AxioImager Z1 Axiophot wide-field fluorescence
microscope and were analyzed by Zeiss AxioVision soft-
ware (Zeiss, Thornwood, NY).
Immunoblot
IMG and C6 glioma cells were incubated for 24 h in full
growth medium plus 100 ng/mL IL-6 to allow for astro-
cytic differentiation of C6 glioma cells [21]. For cytosolic
protein extracts, cells were lysed in hypotonic buffer
using 1 % NP-40 plus protease inhibitors (Calbiochem
Cat. No. 539134; 1:100 dilution) on ice followed by cen-
trifugation to separate the remaining nuclei (pellet) from
the cytosolic fraction (supernatant). The nuclei-
containing pellets were lysed with RIPA buffer plus pro-
tease inhibitors for 30 min on ice. Protein concentration
was determined, and 30–50 μg of protein/sample was
heated for 5 min at 95 °C, cooled on ice, and then re-
solved on a 4–15 % SDS-PAGE gel (10 % SDS-PAGE gel
used for cytosolic and nuclear extracts). The protein was
transferred onto a nitrocellulose membrane (0.2 μm)
using a Trans-blot turbo transfer system (Bio-Rad,
Hercules, CA). The resulting membrane was blocked for
1 h at room temperature in TBST (Tris-buffered saline
plus 0.05 % Tween-20) plus 5 % milk. After three washes
with TBST, the membrane was incubated with primary
mouse monoclonal GFAP (GA5) antibody (1:1000 dilu-
tion; Cell Signaling Technology, Beverly, MA), rabbit
monoclonal NeuN antibody (1:1000 dilution; Abcam
Inc., Cambridge, MA), rat monoclonal F4/80 antibody
(1:10,000 dilution; AbD Serotec), rabbit polyclonal β-
tubulin antibody (1:500; Abcam), or rabbit monoclonal
Lamin B1 antibody (1:10,000 dilution; Abcam) in TBST
plus 5 % milk overnight at 4 °C. The membrane was
washed three times with TBST and then was incubated
for 1 h at room temperature with IRDye 800CW donkey
anti-mouse or anti-rabbit IgG (1:5000 dilution; Li-Cor,
Lincoln, NE) in TBST 5 % milk (anti-rat HRP 1:5000 di-
lution was used to probe for F4/80 primary antibody).
The membrane was washed three times with TBST and
was imaged using Li-Cor Odyssey 2.1 infrared detection
technology.
Quantitative RT-PCR
Total RNA was extracted from IMG or BV-2 cells using
TRIzol reagent (Invitrogen, Carlsbad, CA) as per the
manufacturer’s instructions. For analysis of adult micro-
glial markers, microglia were pre-incubated for 5 days in
full growth medium plus mouse recombinant carrier-
free MCSF (10 ng/mL; R&D Systems) and recombinant
TGFβ1 (50 ng/mL; Miltenyi Biotec) as described [26].
RNA was purified and on-column DNAse treated using
the Direct-zol RNA Miniprep Kit from Zymo-research
(Irvine, CA) as per the manufacturer’s instructions. Puri-
fied RNA was then reverse-transcribed using the Super-
Script® III First-Strand Synthesis System (Invitrogen)
along with oligo(dT)20 primers and random hexamers.
Quantitative PCR was performed using iTaq Universal
SYBR green Supermix (Bio-Rad, Hercules, CA) and the
StepOnePlus Real-Time PCR System (Life Technologies,
Grand Island, NY). In all cases, 36B4 was used as an in-
ternal control. Primers used for quantitative PCR (qPCR)
are listed in Table 1.
Enzyme-linked immunosorbent assays
Mini enzyme-linked immunosorbent assay (ELISA) devel-
opment kits (Peprotech, Rocky Hill, NJ) were used to de-
tect murine TNF-α, IL-6, and IL-1β expression by IMG
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cells. Buffers used throughout this protocol were pur-
chased as an ELISA Buffer Kit from Peprotech (Catalog
#900-K00). Briefly, IMG cells were incubated for 16 h with
either LPS (10 ng/mL) or IL-4 (10 ng/mL) in a six-well tis-
sue culture dish. Alternatively, IMG cells were incubated
for 6 h with or without LPS (10 ng/mL) in 1 mL of full
growth media at 37 °C 5 % CO2. Ac-YVAD-CMK (40 μM)
was then added to the appropriate wells for 5 min prior to
the addition of ATP (5 mM) for 30 min. After the 6- or
16-h incubation, the conditioned media were collected
and the cells were washed three times with PBS and were
lysed for 30 min at 4 °C with 1 % NP-40 plus protease in-
hibitors. Appropriate capture antibody was adhered to
wells of a 96-well plate overnight at room temperature.
After repeated washes, the wells were blocked with 1 %
BSA in PBS for 1 h at room temperature followed by mul-
tiple washes. For each condition, 100-μL aliquots of cell
lysates were added to each well in triplicate for 2 h at
room temperature. The plate was washed repeatedly, and
detection antibody (0.5 μg/mL) was added and incubated
for 1 h at room temperature. Plates were washed and in-
cubated with avidin-HRP conjugate (1:2000 dilution) for
30 min at room temperature. Lastly, the plates were
washed, and 2,2′-Azinobis [3-ethylbenzothiazoline-6-sul-
fonic acid]-diammonium salt (ABTS) liquid substrate was
added to each well. Color development (405 nm) was
monitored using a BioTek Synergy 2 spectrophotometer
(Winooski, VT).
IL-1β immunoblot
IMG cells in a six-well poly-D-lysine-coated tissue cul-
ture dish were treated for 6 h with or without LPS
(10 ng/mL) in 1 mL of full growth media at 37 °C 5 %
CO2. Ac-YVAD-CMK (40 μM) was then added to the
appropriate wells for 5 min prior to the addition of ATP
(5 mM) for 30 min. The IMG cell-conditioned media
were then collected and concentrated ten times from
1 mL to 100 μL using a 10K MWCO Nanosep Omega
centrifugal device (PALL, Ann Arbor, MI). Seven micro-
liters of this media was heated at 95 °C for 5 min and
then resolved on a 4–20 % SDS-PAGE gel. The protein
was then transferred onto a 0.2-μm nitrocellulose mem-
brane using a wet-transfer apparatus at 100 V for
60 min. The membrane was blocked with 5 % milk in
TBST at 4 °C for 1 h prior to incubation overnight at 4 °
C with goat polyclonal IL-1β antibody (1:500 dilution;
Santa Cruz Biotechnology, Inc.). The membrane was
washed three times with TBST and then was incubated
for 1 h at room temperature with IRDye 800CW donkey
anti-goat IgG (1:5000 dilution; Li-Cor) in TBST 3 %
milk. The membrane was washed three times with TBST
and was imaged using Li-Cor Odyssey 2.1 infrared de-
tection technology.
Phagocytosis assays
IMG cells were seeded into two six-well tissue culture
plates (0.5 × 106 cells/well) and allowed to adhere for
2 h, after which time the media were exchanged with
fresh media to remove non-adherent cells. IMG cells
were allowed to grow for 16 h at 37 °C/5 % CO2 prior to
the start of the assay. Sixty-five-microliter aliquots of
carboxylate-modified polystyrene fluorescent yellow-
green latex beads (YG beads) (Sigma Aldrich, Cat#
L4655) were diluted in 6.5-mL aliquots of pre-warmed
(37 °C) or pre-chilled (4 °C) growth media. Media were
removed from IMG cells, and 1 mL of YG bead-
containing media was added to each well. IMG cells
were immediately incubated at 37 °C or chilled at 4 °C
for 1 h. The remaining steps were strictly performed on
ice. To remove non-internalized beads, cells were
washed five times with 2 mL/well ice-cold PBS. After
washing, the IMG cells were incubated with 2 mL/well
ice-cold PBS containing 2 mM EDTA for 10 min at 4 °C.
Cells were removed from the dish by titration and trans-
ferred to 15-mL conical tubes. Cells were collected by
centrifugation at 300×g for 6 min at 4 °C. Cell pellets
Table 1 Primer list used for qPCR
Transcript Forward primer Reverse primer
Mouse 36B4 AGATGCAGCAGATCCGCAT GTTCTTGCCCATCAGCACC
Mouse iNOS GTTCTCAGCCCAACAATACAAGA GTGGACGGGTCGATGTCAC
Mouse TNF-α AAATGGCCTCCCTCTCATCAG GTCACTCGAATTTTGAGAAGATGATC
Mouse IL-1β AGCTTCAGGCAGGCAGTATC AAGGTCCACGGGAAAGACAC
Mouse Arg-1 CACAGTCTGGCAGTTGGAAG GGGAGTGTTGATGTCAGTGTG
Mouse Mgl1 GCGAAGGCTTACAATGATATACGAAAACCTCC GCGCTCAGACGAGAGCTCCTAGCTCTCC
Mouse Ym1 AGAAGGGAGTTTCAAACCTGGT GTCTTGCTCATGTGTGTAAGTGA
Mouse Itgb5 CTCCAGGGCCCGTTATGAAA AGGCGAAATCGACAGTGTGT
Mouse Tgfb1 AGGGCTACCATGCCAACTTC CCACGTAGTAGACGATGGGC
Mouse Fcrls AAGTGCGTTTGGTGAATGGC CACAGCCACATCCCTCATGT
Mouse Sall1 TGCTGACCAACGACTCTTCC ACTGGGGTGGGAGATAGACC
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were resuspended in PBS containing 2 mM EDTA. IMG
cell-acquired YG beads were quantified by flow cytome-
try, and data were analyzed.
Amyloid-beta assays
Amyloid-beta (1–42), FITC-amyloid-beta (1–42), and
scrambled amyloid-beta (1–42) were purchased from
rPeptide (Bogart, GA). Briefly, HFIP-prepared peptide
was resuspended with DMSO (0.1 mg in 10 μL) and
then diluted 1:10 with Ham’s F-12 nutrient mix and
incubated for 24 h at 4 °C as described [22, 23]. Both
oligomeric and fibrillar Aβ1–42 were detected by dot
blot analyses using species-specific antibodies (Add-
itional file 1: Figure S1). IMG phagocytosis of FITC-
Aβ was performed using cells seeded into a 96-well
black-walled amine-coated tissue culture plate. Cells
were incubated with FITC-Aβ1–42 (1 μM) at 37 °C
5 % CO2 for the times indicated in full growth
medium. Cells were placed on ice and washed five
times with ice-cold PBS++. One hundred microliters
of PBS++ was added to each well, and FITC fluores-
cence was measured using a plate reader (excitation
494 nm, emission 521 nm).
Indirect immunofluorescence was used to determine
subcellular localization of FITC-Aβ. IMG cells grown on
glass coverslips were incubated for 1 h with FITC-Aβ
and processed for fluorescence microscopy as described
above. Briefly, cells were incubated with primary anti-
body targeting lysosomal-associated membrane protein 1
(LAMP1) (Pharmingen; 1:100 dilution). Secondary anti-
rat rhodamine red antibody (JacksonImmuno Research;
1:1000 dilution) was used. Each antibody treatment was
performed at room temperature for 1 h in 1 % BSA
PBS++. Cells were then washed, mounted, and imaged
as described above. Co-localized pixels were deter-
mined using ImageJ 1.48v software (National Institute
of Health, USA).
Statistical analysis
One-way ANOVA followed by Tukey’s multiple com-
parison test was used where indicated. Two-way
ANOVA followed by Dunnett’s multiple comparison test
was used where indicated. Paired t test statistical analysis
was used where indicated. Statistical analyses were per-
formed using Prism GraphPad version 6.00 for Win-
dows, GraphPad Software, La Jolla, CA, USA.
Fig. 1 IMG cells display similar morphology to primary microglia and express the microglia markers CD11b and F4/80. a Representative DIC
images of IMG, BV-2, and primary adult microglial cells. Images are at ×40 magnification. b Flow cytometry of IMG cells. Representative zebra plot
(left panel) of IMG showing a population of >95 % was gated for the analysis of IMG F4/80 (middle panel) and CD11b (right panel) expression (filled
trace) by flow cytometry. Isotype controls (open trace) are also included in the graphs
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Fig. 2 IMG cells express markers specific to microglia. a Immunofluorescence microscopy was used to assess the expression of the microglia markers
CD11b and F4/80 by IMG and SH-SY5Y cells. Indirect immunofluorescence was used to assess the expression of the neuronal marker NeuN by IMG
and SH-SY5Y cells. Images are at ×40 magnification. DIC images paired with each fluorescent image are shown. b Immunoblot of IMG and either SH-
SY5Y or C6 glioma cell extracts. Whole-cell extracts are used unless otherwise indicated. Blots were probed for NeuN, GFAP, or F4/80. Loading controls
were β-tubulin (whole cell) and Lamin B1 (nuclear extracts). c Quantitative PCR was used to assess transcript levels of the microglia-specific markers
Fcrls, Itgb5, and Sall1 in IMG and BV-2 cells. A paired t test was used to determine the significance of the data. *P < 0.05; **P < 0.005; ***P < 0.001; n.s. is
not significant. Data are represented as means ± s.d. (n = 3, technical replicates). Each experiment was repeated on at least two separate occasions
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Results
IMG cells display morphology similar to primary microglia
and express the microglial markers CD11b and F4/80
Phase-contrast images show that IMG, BV-2, and pri-
mary adult microglial cells are similar in cell morph-
ology and size (Fig. 1a). The morphology of microglia
is dependent upon their activation state; activated or
dividing microglia are amoeboid-shaped whereas rest-
ing microglia display a ramified morphology [24].
Both IMG and BV-2 are rapidly dividing immortalized
cells containing mostly amoeboid (dividing) with few
ramified cells.
Expression of two microglia-specific markers,
CD11b and F4/80, was determined by flow cytometry
[3]. Both CD11b and F4/80 are detected in mouse
brain after embryonic day 9.5 [16, 25]. Indeed, these
markers are expressed by IMG cells as indicated by
flow cytometry (Fig. 1b; filled trace); isotype controls
are used to account for non-specific binding (Fig. 1b;
open trace). We further confirmed the expression of
CD11b and F4/80 using fluorescence microscopy
(Fig. 2a); both CD11b and F4/80 were detected in
IMG cells but not in SH-SY5Y cells, a neuronal cell
line. Conversely, the neuron-specific marker NeuN
was detected in SH-SY5Y cells and to a lesser extent
in IMG cells (Fig. 2b). Western blot analysis con-
firmed NeuN staining was specific, as some protein
was detected in IMG nuclear extracts. Western blot
analysis also detected the astrocyte-specific marker
GFAP in C6 glioma cell lysates but not in IMG cell
lysates (Fig. 2b). Recent work has identified several
genes unique to adult microglia [26]. Transcript levels
of three of the four genes tested (Fcrls, Itgb5, Sall1,
and Tgfb1) are significantly greater in IMG cells com-
pared to BV-2 cells (Fig. 2c). These combined data
suggest that IMG cells are a pure population with
both morphology and biomarkers associated with
adult microglia [16].
IMG cells respond to exogenous pro- and anti-
inflammatory stimuli
Adult microglial cells characteristically polarize to either
pro- or anti-inflammatory state in response to alter-
ations in their local microenvironment [1]. A number of
signaling molecules have been identified that induce re-
active/reparative polarization of microglial cells. IMG
cells were exposed for 8 or 24 h to induce either the re-
active pro-inflammatory phenotype (LPS, IFNγ, IL-1β,
and TNF-α) or the reparative anti-inflammatory pheno-
type (IL-4 and IL-13) [1, 3]. After incubation with the
appropriate signaling molecules, RNA was isolated and
qPCR was performed to determine the state of IMG ac-
tivation. Markers indicative of reactive polarization that
were assessed via qPCR included inducible nitric oxide
synthase (iNOS), TNF-α, and IL-1β transcripts while
markers indicative of the anti-inflammatory response in-
cluded Arg-1, Mgl1, and Ym1 transcripts. The results
show that IMG cells transition to a reactive phenotype
when incubated for 8 or 24 h with LPS, IFNγ, and to a
lesser extent IL-1β and TNF-α (Fig. 3a). Conversely,
IMG cells express anti-inflammatory markers when in-
cubated for 8 or 24 h with IL-4 and IL-13 (Fig. 3b). As
similar changes in transcript abundance were noted in
IMG cells treated with stimuli for 8 or 24 h, we per-
formed all incubations with LPS or IL-4 for a period of
16 h in later experiments. Taken together, these data in-
dicate that IMG cells retain the ability to polarize to the
pro- or anti-inflammatory state, a functional feature of
microglia that is well-documented by the literature [1].
As IMG cells are activated by incubation with LPS
(Fig. 3a), we hypothesized protein production of secreted
pro-inflammatory factors would increase. To test this,
an ELISA was used to determine relative abundance of
the cytokines IL-6 and TNF-α in IMG cell-conditioned
media after incubation with LPS. ELISA results con-
firmed that exposure to LPS for 16 h yielded a signifi-
cant increase in IL-6 and TNF-α (Fig. 4a); no significant
change in expression of these cytokines was noted when
cells were exposed to IL-4 for 16 h. LPS also increased
synthesis of IL-1β, detected by ELISA in IMG cell lysates
(Fig. 4b). Inflammasome activation and caspase-1-
mediated cleavage of pro-IL-1β is required for secretion
of mature IL-1β by LPS-primed microglia [27]. Activa-
tion of the NLRP3 inflammasome in LPS-primed IMG
cells by treatment with ATP significantly enhanced se-
cretion of IL-1β into conditioned media (Fig. 4c);
addition of the caspase-1 inhibitor Ac-YVAD-CMK ab-
rogated this effect. Treatment of LPS-primed IMG cells
with ATP resulted in processing and secretion of the 17-
kDa mature form of IL-1β into the media (Fig. 4d).
Cleavage to the mature form was inhibited by Ac-
YVAD-CMK (Fig. 4d). Thus, LPS upregulates synthesis,
processing, and secretion of mature IL-1β by IMG cells
in an appropriate two-step process.
IMG cells display a more robust response than BV-2 cells
to pro- and anti-inflammatory stimuli
BV-2 cells have been often used to examine micro-
glial cell function. However, this cell line responds
poorly to pro- and anti-inflammatory stimuli (LPS
and IL-4, respectively) [14, 28–31]. We directly com-
pared IMG and BV-2 responses to LPS or IL-4 upon
16-h exposure. Transcript abundance of both iNOS
and Arg-1 was monitored via qPCR (Fig. 5). IMG
cells increase the production of iNOS (>200-fold) or
Arg-1 (>100-fold) transcripts compared to BV-2 cells
upon exposure to either LPS or IL-4, respectively.
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Fig. 3 (See legend on next page.)
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In the Alzheimer’s brain, microglia are polarized to a
reactive state by Aβ peptides in the interstitium. We
compared the efficacy of Aβ on iNOS production in
IMG and BV-2 cells. The transcript abundance of iNOS
within both IMG and BV-2 cells increased as a conse-
quence of increasing Aβ concentration (Fig. 5b, c);
scrambled Aβ peptide had no measurable effect. Not-
ably, the increase in Aβ-induced iNOS expression by
IMG cells (approx. 2500-fold at 5 μM Aβ) was far
greater than that observed in BV-2 cells (approx. 350-
fold at 5 μM Aβ). IMG cell nitrite production was
increased with Aβ treatment as determined by the Griess
assay (data not shown).
IMG cells phagocytose foreign particles
When confronted with foreign particles such as dead or
dying neurons, microglia will remove these materials via
phagocytosis [11, 32]. To test their phagocytic potential,
IMG cells were exposed to 1-μm-diameter carboxylate-
modified polystyrene fluorescent YG beads for 1 h at
37 °C. Internalization of the YG beads by IMG cells was
evaluated by fluorescence microscopy. A series of z-
Fig. 4 IMG cells respond to LPS treatment by increasing protein expression of inflammatory cytokines. a ELISA was used to analyze the secretion
of TNF-α and IL-6 into IMG cell-conditioned medium during a 16-h incubation with or without LPS (10 ng/mL) or IL-4 (10 ng/mL) as described in
the “Methods” section. b ELISA analysis of IL-1β in whole-cell lysates of IMG cells treated as described in (a). c ELISA of conditioned media (filled
bars) and cell lysates (open bars) collected from IMG cells treated with or without LPS (10 ng/mL) for 6 h. LPS-treated cells were also incubated
with or without Ac-YVAD-CMK (40 μM; YVAD) for 5 min, followed by ATP (5 mM) for 30 min as indicated. d Immunoblot analysis of conditioned
media from IMG cells treated as described in (c). Blots were probed for IL-1β. Pro- (34 kDa) and mature (17 kDa) IL-1β bands are indicated.
One-way ANOVA was used to determine the significance of the data. *P < 0.01; **P < 0.0001. Data are represented as means ± s.d. (n = 3, technical
replicates). Each experiment was repeated on at least two separate occasions
(See figure on previous page.)
Fig. 3 Response of IMG cells to pro- and anti-inflammatory stimuli. IMG cells were treated for either 8 or 24 h with LPS (10 ng/mL), interferon
gamma (IFNγ) (10 ng/mL), IL-1β (10 ng/mL), TNF-α (5 ng/mL), IL-4 (10 ng/mL), IL-13 (10 ng/mL), IL-6 (10 ng/mL), or TGF-β (50 ng/mL). iNOS, TNF-
α, and IL-1β message levels were used as markers for the microglial pro-inflammatory phenotype (a), whereas Arg-1, Mgl1, and Ym1 were used as
markers for an anti-inflammatory phenotype (b). Quantitative PCR was used to assess the changes in message levels of the aforementioned genes
relative to the internal control 36B4. Average of biological duplicates are shown with similar results obtained in at least two different experiments
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stack images were acquired to examine the localization
of YG beads (shown in green) within a single IMG cell
(identified by the microglial marker CD11b (purple))
(Fig. 6a). The compilation of images provided by the z-
stack clearly indicates that this particular IMG cell
engulfed at least two YG beads, as shown by their intra-
cellular localization (Fig. 6a, arrows). Cross-sectional im-
ages of the same IMG cell are shown in Fig. 6b.
Next, we used flow cytometry to quantify the number
of beads phagocytosed per IMG cell. Again, IMG cells
were incubated with YG beads for 1 h at 37 °C to allow
time for phagocytosis to occur. Simultaneously, a dish of
IMG cells was incubated with YG beads for 1 h at 4 °C
to account for non-specific binding. After exposure to
YG beads, IMG cells were washed thoroughly and ana-
lyzed for yellow-green fluorescence via flow cytometry.
By monitoring the degree of fluorescent intensity, popu-
lations of IMG cells which have ingested 0, 1, 2, 3, or 4
beads can be differentiated (Fig. 7a, see labels in the
middle graph). These data are quantitatively similar to
phagocytosis of YG beads by BV-2 cells (Fig. 7b, c).
In the Alzheimer’s brain, a major function of micro-
glial is to clear Aβ by phagocytosis. To study uptake of
Aβ, IMG cells were incubated at 37 °C with 1 μM FITC-
Aβ for the indicated times and washed, and then intern-
alization was analyzed using a fluorescence plate reader.
These data show that IMG phagocytosis of FITC-Aβ is
time-dependent and maximal within 3 h (Fig. 7d). We
hypothesized that a portion of the Aβ phagocytosed by
IMG cells would be trafficked to the phagolysosome
within this time frame. Immunofluorescence microscopy
confirmed that a fraction of the FITC-Aβ phagocytosed
by IMG during a 1-h incubation period co-localized with
the LAMP1 (Fig. 7e).
Aβ-induced iNOS expression by IMG cells is blocked by
cannabinoids
Since IMG cells display the same characteristics as pri-
mary microglia, the idea that this cell model system
could be used for candidate drug screens in the treat-
ment of Alzheimer’s disease is well-supported. To evalu-
ate their use in pharmacological studies, we examined
the effects of the cannabinoids THC and JWH-015 on
Aβ-induced iNOS gene expression. Prolonged use of
cannabinoids is reported to reduce inflammation in the
brains of Alzheimer’s disease model mice [33]; cannabi-
noids have also been shown to reduce microglial activa-
tion both in vitro and in vivo [34, 35]. The principal
Fig. 5 IMG cells are significantly more sensitive to polarization by LPS, Aβ, and IL-4 than are BV-2 cells. a Quantitative PCR was used to analyze
the transcript abundance of iNOS and Arg-1 in IMG cells and BV-2 cells treated with or without LPS (10 ng/mL) or IL-4 (10 ng/mL) for 16 h. b, c
IMG and BV-2 cells were treated with Aβ1–42 peptide or scrambled Aβ1–42 peptide at varying concentrations as indicated for 6 h. The transcript
abundance of iNOS was determined via qPCR. One-way (b) and two-way (a) ANOVA statistical analyses were used to determine the significance
of the data. *P < 0.0001. Data are represented as means ± s.d. (n = 3, technical replicates). Each experiment was repeated in triplicate
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psychoactive constituent of cannabis, THC, significantly
inhibited the Aβ-induced increase in iNOS transcript
levels within IMG cells (Fig. 8a). THC is an agonist to
both cannabinoid receptor type 1 (CB1; psychoactive)
and type 2 (CB2; non-psychoactive). JWH-015 is a select-
ive CB2 agonist. Like THC, JWH-015 (50 μM) inhibited
Fig. 6 IMG cells internalize fluorescent latex beads. Images of IMG cells that were incubated with fluorescent latex beads for 1 h at 37 °C 5 % CO2
were obtained. CD11b (purple) was used as a marker for IMG cells. a Z-stack series of microscopic images of an IMG cell (purple) were compiled
into a grid to demonstrate the internal localization of two fluorescent latex beads (green dots; indicated by arrows). b Z-stack series from (a) is ac-
companied by two cross-sectional perspectives. The images were obtained with a ×100 objective. DAPI (blue) stains the nucleus
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Aβ-induced iNOS expression and in a time-dependent
manner (Fig. 8b). In a dosing experiment, we determined
the effect of JWH-015 on Aβ-induced IMG iNOS levels
is reproducible even at a lower dose (5 μM) (Fig. 8c).
Neither drug altered the expression of the M2 marker
Arg-1 in Aβ-treated IMG cells (data not shown). These
data are consistent with previous results in the literature
demonstrating cannabinoid-mediated prevention of Aβ-
induced microglial activation [35]. Combined, this evi-
dence demonstrates the pharmacological intervention of
Aβ-induced M1 activation of IMG cells.
Discussion
Chronically activated pro-inflammatory adult micro-
glial cells contribute to the progression of neurode-
generative diseases like Alzheimer’s and Parkinson’s
Fig. 7 IMG cells retain phagocytic properties inherent in microglial cells. Phagocytosis of 1-μm fluorescent yellow-green latex beads (YG beads) by IMG
(a) or BV-2 (b) cells as analyzed by flow cytometry. Cells were incubated with the YG beads for 1 h at either 4 °C (open trace) or 37 °C (gray fill) prior to
analysis by flow cytometry. Each peak represents the IMG population which has ingested either 0, 1, 2, 3, or 4 beads, respectively. Each graph (a, b) is a
representation of data from at least three biological replicates. c Percentage of cells which acquired ≥1 YG beads as analyzed by flow cytometry. d
Kinetic analysis of oligomeric FITC-Aβ uptake by IMG. IMG cells were incubated with FITC-Aβ (1 μM) for the indicated times at 37 °C. IMG-associated
FITC fluorescence was measured using a plate reader. e Subcellular localization of internalized FITC-Aβ was assessed using fluorescence microscopy.
IMG cells were incubated for 1 h with FITC-Aβ (green) prior to being processed for microscopy. Phagolysosomes were identified using LAMP1 antibody
(red). Areas of co-localization (white) were determined using ImageJ software. A paired t test was used to determine the significance of the data
(n.s. is not significant). Data are represented as means ± s.d. (n = 3, experimental replicates)
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diseases [4, 5, 9, 10]. An adult immortalized microglial cell
model system for examination of neuroinflammation is
therefore essential. BV-2 cells, a currently used model sys-
tem, were generated using mononuclear cells from an em-
bryonic mouse brain. A major drawback is the limited
BV-2 cell response to pro- and anti-inflammatory stimuli
(Fig. 6) [14, 15, 29–31]. On the other hand, primary adult
microglial cell isolation yields a limited number of cells,
can be technically challenging with potential cell activa-
tion, and suffers from a lack of homogeneity.
Here, we describe the development of a novel immortal-
ized adult microglial cell line, IMG cells, which share
phenotypic attributes with primary adult microglia and re-
spond robustly to inflammatory signals. Primary adult
microglia react to changes in their extracellular environ-
ment by polarizing to a reactive phenotype or one that pro-
motes resolution of inflammation [10, 36]. IMG cells are
far more responsive than BV-2 cells to external pro- and
anti-inflammatory signals such as LPS and IL-4. The fact
that IMG cells display a robust response to external pro-
and anti-inflammatory stimuli make this an ideal model
system to examine microglial involvement in neurodegen-
erative diseases, such as Alzheimer’s disease, where a link
between chronic microglial activation and the progression
of the disease has been well established [5, 37].
In the early stages of Alzheimer’s disease, brain
microglia become activated by Aβ peptides which, in
turn, are cleared by the microglia via phagocytosis
[11, 38–40]. The activation of microglia by Aβ pep-
tides increases secretion of pro-inflammatory cyto-
kines, which can reduce microglial cell Aβ peptide
receptor expression via an autocrine feedback loop
[38, 41]. The reduced expression of Aβ receptors by
microglia results in reduced clearance, thus promoting
plaque formation to persist and disease progression to
continue. Secretion of pro-inflammatory cytokines by
activated microglia also promotes neuronal cell dam-
age and death. It is therefore important to understand
microglial cell function, especially Aβ-induced activa-
tion and phagocytosis, in order to develop new ther-
apies aimed at targeting these pro-inflammatory
effects. We have developed and characterized the
IMG cell line to advance towards these goals.
Taming the chronic pro-inflammatory polarization
of microglia in Alzheimer’s disease is one therapeutic
strategy that is actively investigated [2]. In the past,
BV-2 cells have been used to screen for potential
anti-inflammatory drugs to quell or negate the effect
of LPS [30]. Our experiments show that the IMG
cells’ response to inflammatory factors is far greater
than that of BV-2 cells, raising the promise of their
utility in such screening efforts. Moreover, IMG cells
are highly reactive to Aβ, establishing an in vitro
model relevant to Alzheimer’s disease. To explore
their potential use in pharmacological studies, we
established that the cannabinoids THC and JWH-015
limit Aβ-induced IMG cell inflammation. The mech-
anism of anti-inflammatory action of cannabinoids
has yet to be established, but our studies suggest CB2
activation by the selective agonist JWH-015 is sufficient to
mediate this effect. In preliminary experiments, we have
determined that cannabinoids do not alter Aβ uptake or
degradation by IMG cells (data not shown). CB2 may
elicit downstream signals to reduce the Aβ-induced in-
flammatory response in IMG cells. Potential targets in-
clude elements of the peroxisome proliferator-activated
receptor-γ (PPAR-γ) pathway [42]. Further investigation is
required to determine the exact mechanism of
Fig. 8 Cannabinoids inhibit Aβ-induced iNOS production in IMG cells. Quantitative PCR was used to analyze the transcript abundance of iNOS in
IMG cells. a IMG cells were treated with or without Aβ and/or THC for 6 h at 37 °C. IMG cells were incubated with Aβ (1 μM; 6 h) and the CB2
selective agonist JWH-015 (50 μM) for the indicated times (b) or at varying concentrations (c). One-way ANOVA statistical analyses were used to
determine the significance of the data. *P < 0.005; **P < 0.0001. Data are represented as means ± s.d. (n = 3, technical replicates)
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cannabinoid drug action on IMG cells and to employ
these cells to screen for new drug candidates that amelior-
ate Aβ-induced inflammation.
Conclusions
We have established an immortalized cell line from adult
murine microglia. We conclude this model system,
called IMG for immortalized microglia, fully recapitu-
lates morphological and functional characteristics of
brain microglia. IMG cells express microglia-specific
markers and respond appropriately to pro- and anti-
inflammatory stimuli. IMG cells phagocytose foreign
particles. Moreover, IMG cells are robustly activated by
Aβ1–42, which they also phagocytose. The response of
IMG cells to extracellular pro- and anti-inflammatory
stimuli, including Aβ, is far greater than the most com-
monly employed microglial BV-2 cell line. As an example
of their potential utility, we demonstrate administration of
cannabinoids can effectively alleviate Aβ activation of IMG
cells. This cell line provides a new platform to explore
drug interactions and gain mechanistic information about
neuroinflammatory responses underlying Alzheimer’s
disease and other neurological disorders.
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